Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Thalidomide and its derivatives are the only protein degraders currently used in clinical practice. This tutorial review provides an overview of the mechanism of action of thalidomide-based degraders and their future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Self-citationLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Self-citationAnticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
Self-citationSchneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Self-citationModular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Plasticity in binding confers selectivity in ligand-induced protein degradation
Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338
Al-Baradie, R., Yamada, K., St. Hilaire, C., Chan, W.-M., Andrews, C., McIntosh, N., Nakano, M., Martonyi, E. J., Raymond, W. R., Okumura, S., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/343821 · Cited by 314
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01921 · Cited by 309
A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation
Higgins, J. J., Pucilowska, J., Lombardi, R. Q., & Rooney, J. P. (2004) · Neurology · doi:10.1212/01.wnl.0000146196.01316.a2 · Cited by 250
Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood · doi:10.1182/blood.2020008676 · Cited by 229
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Van Nguyen, T., Lee, J. E., Sweredoski, M. J., Yang, S.-J., Jeon, S.-J., Harrison, J. S., Yim, J.-H., Lee, S. G., Handa, H., Kuhlman, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.032 · Cited by 177
Self-citationpSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0366-7 · Cited by 134
Self-citationCrbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability
Huart, A.-S., MacLaine, N. J., Meek, D. W., & Hupp, T. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052647 · Cited by 110
Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex
Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0405-9 · Cited by 103
Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
Furihata, H., Yamanaka, S., Honda, T., Miyauchi, Y., Asano, A., Shibata, N., Tanokura, M., Sawasaki, T., & Miyakawa, T. (2020) · Nature Communications · doi:10.1038/s41467-020-18488-4 · Cited by 89
Yamanaka, S., Murai, H., Saito, D., Abe, G., Tokunaga, E., Iwasaki, T., Takahashi, H., Takeda, H., Suzuki, T., Shibata, N., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105375 · Cited by 89
Thalidomide mimics uridine binding to an aromatic cage in cereblon
Hartmann, M. D., Boichenko, I., Coles, M., Zanini, F., Lupas, A. N., & Hernandez Alvarez, B. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.10.010 · Cited by 83
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife · doi:10.7554/elife.40958 · Cited by 78
Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212916 · Cited by 78
Lee, K. M., Yang, S.-J., Kim, Y. D., Choi, Y. D., Nam, J. H., Choi, C. S., Choi, H.-S., & Park, C.-S. (2013) · Diabetes · doi:10.2337/db12-1030 · Cited by 77
Chen, Y.-A., Peng, Y.-J., Hu, M.-C., Huang, J.-J., Chien, Y.-C., Wu, J.-T., Chen, T.-Y., & Tang, C.-Y. (2015) · Scientific Reports · doi:10.1038/srep10667 · Cited by 61
Pourabdollah, M., Bahmanyar, M., Atenafu, E. G., Reece, D., Hou, J., & Chang, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0354-2 · Cited by 24
Research works printed but not linked: 60
- Yamamoto, 2020, Nat. Chem. Biol., 16, 1208, 10.1038/s41589-020-0645-3 · DOI
- Shimizu, 2021, Commun. Biol., 4, 277, 10.1038/s42003-021-01785-z · DOI
- Renneville, 2021, Blood Cancer Discovery, 2, 250, 10.1158/2643-3230.BCD-20-0105 · DOI
- Yamanaka, 2022, Nat. Commun., 13, 183, 10.1038/s41467-021-27818-z · DOI
- Burley, 1962, Lancet, 279, 271, 10.1016/S0140-6736(62)91217-5 · DOI · Paper page
- Lenz, 1988, Teratology, 38, 203, 10.1002/tera.1420380303 · DOI · Paper page
- Sheskin, 1965, Clin. Pharm. Ther., 6, 303, 10.1002/cpt196563303 · DOI · Paper page
- Sampaio, 1991, J. Exp. Med., 173, 699, 10.1084/jem.173.3.699 · DOI · Paper page
- Mchugh, 1995, Clin. Exp. Immunol., 99, 160, 10.1111/j.1365-2249.1995.tb05527.x · DOI · Paper page
- Dredge, 2002, J. Immunol., 168, 4914, 10.4049/jimmunol.168.10.4914 · DOI · Paper page
- Marriott, 2002, Clin. Exp. Immunol., 130, 75, 10.1046/j.1365-2249.2002.01954.x · DOI · Paper page
- Nishio, 2008, Colloids Surf., B, 64, 162, 10.1016/j.colsurfb.2008.01.013 · doi:10.1016/j.colsurfb.2008.01.013
- Masaike, 2009, Mol. Pharmacol., 77, 262, 10.1124/mol.109.059006 · doi:10.1124/mol.109.059006
- Azuma, 2008, PLoS One, 3, e3070, 10.1371/journal.pone.0003070 · DOI
- Kuramori, 2009, Biochem. Biophys. Res. Commun., 379, 519, 10.1016/j.bbrc.2008.12.103 · doi:10.1016/j.bbrc.2008.12.103
- Zhu, 2011, Blood, 118, 4771, 10.1182/blood-2011-05-356063 · DOI · Paper page
- Broyl, 2013, Blood, 121, 624, 10.1182/blood-2012-06-438101 · DOI · Paper page
- Heintel, 2013, Br. J. Haematol., 161, 695, 10.1111/bjh.12338 · DOI · Paper page
- Zhu, 2014, Blood, 124, 536, 10.1182/blood-2014-02-557819 · DOI · Paper page
- Krönke, 2016, Leukemia, 31, 1363, 10.1038/leu.2016.384 · DOI · Paper page
- Misiewicz-Krzeminska, 2020, Blood Adv., 4, 6023, 10.1182/bloodadvances.2020002711 · DOI
- Amit, 2002, Genes Dev., 16, 1066, 10.1101/gad.230302 · DOI · Paper page
- Bidère, 2008, Nature, 458, 92, 10.1038/nature07613 · DOI · Paper page
- Corral, 1999, J. Immunol., 163, 380, 10.4049/jimmunol.163.1.380 · DOI · Paper page
- Schafer, 2003, J. Pharmacol. Exp. Ther., 305, 1222, 10.1124/jpet.102.048496 · DOI · Paper page
- Dredge, 2002, J. Immunol., 168, 4914, 10.4049/jimmunol.168.10.4914 · DOI · Paper page
- Wu, 2008, Clin. Cancer Res., 14, 4650, 10.1158/1078-0432.CCR-07-4405 · DOI · Paper page
- Gandhi, 2013, Br. J. Haematol., 164, 811, 10.1111/bjh.12708 · DOI · Paper page
- Jacques, 2015, Proc. Natl. Acad. Sci. U. S. A., 112, E1471, 10.1073/pnas.1417832112 · DOI
- Mori, 2018, Sci. Rep., 8, 1294, 10.1038/s41598-018-19202-7 · DOI
- Hirose, 2020, Proc. Natl. Acad. Sci. U. S. A., 117, 23106, 10.1073/pnas.1917701117 · DOI
- Kohlhase, 2002, Hum. Mol. Genet., 11, 2979, 10.1093/hmg/11.23.2979 · DOI · Paper page
- Kohlhase, 2004, Birth Defects Res., Part A, 70, 550, 10.1002/bdra.20050 · DOI
- Belair, 2020, Sci. Rep., 10, 2864, 10.1038/s41598-020-59542-x · DOI
- Mills, 1999, Nature, 398, 708, 10.1038/19531 · DOI · Paper page
- Yang, 2002, Trends Genet., 18, 90, 10.1016/S0168-9525(02)02595-7 · DOI · Paper page
- Yang, 1999, Nature, 398, 714, 10.1038/19539 · DOI · Paper page
- Chen, 2015, PLoS One, 10, e0143878, 10.1371/journal.pone.0143878 · doi:10.1371/journal.pone.0143878
- Barna, 2000, Nat. Genet., 25, 166, 10.1038/76014 · DOI · Paper page
- Chamberlain, 2014, Nat. Struct. Mol. Biol., 21, 803, 10.1038/nsmb.2874 · DOI · Paper page
- Li, 2006, Cell, 124, 105, 10.1016/j.cell.2005.10.033 · DOI · Paper page
- Sheereen, 2017, J. Med. Genet., 54, 236, 10.1136/jmedgenet-2016-104117 · DOI · Paper page
- Petzold, 2016, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
- Boichenko, 2018, ACS Omega, 3, 11163, 10.1021/acsomega.8b00959 · DOI
- Heim, 2019, J. Med. Chem., 62, 6615, 10.1021/acs.jmedchem.9b00454 · DOI
- Heim, 2022, Acta Crystallogr., Sect. D: Struct. Biol., 78, 290, 10.1107/S2059798322000092 · DOI
- Maiwald, 2020, ACS Med. Chem. Lett., 12, 74, 10.1021/acsmedchemlett.0c00440 · DOI
- Burslem, 2018, ChemMedChem, 13, 1508, 10.1002/cmdc.201800271 · DOI · Paper page
- Brent, 1964, J. Pediatr., 64, 762, 10.1016/S0022-3476(64)80626-0 · DOI
- Chesi, 2012, Blood, 120, 376, 10.1182/blood-2012-02-412783 · DOI · Paper page
- Gemechu, 2018, Proc. Natl. Acad. Sci. U. S. A., 115, 11802, 10.1073/pnas.1814446115 · DOI · Paper page
- Winter, 2015, Science, 348, 1376, 10.1126/science.aab1433 · DOI · Paper page
- Schiedel, 2017, J. Med. Chem., 61, 482, 10.1021/acs.jmedchem.6b01872 · DOI · Paper page
- Su, 2019, J. Med. Chem., 62, 7575, 10.1021/acs.jmedchem.9b00871 · DOI · Paper page
- Liu, 2020, Sci. Adv., 6, eaay5154, 10.1126/sciadv.aay5154 · DOI · Paper page
- Reynders, 2020, Sci. Adv., 6, eaay5064, 10.1126/sciadv.aay5064 · DOI · Paper page
- Liu, 2014, Nat. Commun., 5, 3924, 10.1038/ncomms4924 · DOI
- Kwon, 2019, FASEB J., 33, 6539, 10.1096/fj.201801766RRR · DOI
- Jo, 2005, J. Neurochem., 94, 1212, 10.1111/j.1471-4159.2005.03344.x · DOI · Paper page
- Song, 2018, PLoS Genet., 14, e1007165, 10.1371/journal.pgen.1007165 · DOI
Cited by
Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
Heim, C., Spring, A.-K., Kirchgäßner, S., Schwarzer, D., & Hartmann, M. D. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.001 · Cited by 51
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
Eladl, O. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117297 · Cited by 44
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
Scalable insect cell expression and purification screening applied to CRL4-DCAF substrate receptors
(2026) · doi:10.1016/j.pep.2026.106907
Metadata
- Authors
- Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2022
- Volume
- 51
- Issue
- 15
- Pages
- 6234-6250
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W4284888202
- Cited by
- 158
- References
- 56
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Japan Society for the Promotion of Science (18H05502, 20H03182, 20K08741, 21H02955)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.